Additionally, EGFR-specific BiTEs were shown to lyse KRAS- and BRAF-mutated CRC cell lines in vitro and inhibit the growth of CRC xenograft tumors, while cetuximab was ineffective [188]. This evidence concerns the gene KRAS and colorectal carcinoma.